Merck KGaA Valuation Multiples

Discover Merck KGaA's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like Regeneron, Chugai Pharma, Takeda Pharmaceuticals, Bayer and more.

Merck KGaA Overview

About Merck KGaA

Merck KGaA operates in three main segments: Life Science, Electronics, and Healthcare. The Life Science segment provides laboratory consumables and instruments to researchers in academia and applied fields, including the biopharmaceutical industry. The Electronics segment offers specialty materials to manufacture a variety of products, such as semiconductors and flat-screen televisions. In the healthcare segment, Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.


Founded

N/A

HQ

Germany

Employees

62.6K

Financials (LTM)

Revenue: $24B
EBITDA: $6.9B

EV

$78B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Merck KGaA Financials

Merck KGaA reported last 12-month revenue of $24B and EBITDA of $6.9B.

In the same LTM period, Merck KGaA generated $14B in gross profit, $6.9B in EBITDA, and $4.1B in net income.

Revenue (LTM)


Merck KGaA P&L

In the most recent fiscal year, Merck KGaA reported revenue of $24B and EBITDA of $7.1B.

Merck KGaA is profitable as of last fiscal year, with gross margin of 58%, EBITDA margin of 29%, and net margin of 17%.

See analyst estimates for Merck KGaA
LTMLast FY202320242025202620272028
Revenue$24B$24B$24B$24B$24B
Gross Profit$14B$14B$14B$14B$14B
Gross Margin59%58%59%59%59%
EBITDA$6.9B$7.1B$6.5B$6.8B$6.9B
EBITDA Margin28%29%27%28%28%
EBIT Margin19%19%17%19%17%
Net Profit$4.1B$4.2B$3.2B$3.2B$3B
Net Margin17%17%13%13%12%
Net Debt-$10B---

Financial data powered by Morningstar, Inc.

Merck KGaA Stock Performance

Merck KGaA has current market cap of $69B, and enterprise value of $78B.

Market Cap Evolution


Merck KGaA's stock price is $157.88.

Merck KGaA share price decreased by 5.9% in the last 30 days, and increased by 24.0% in the last year.

Merck KGaA has an EPS (earnings per share) of $9.66.

See more trading valuation data for Merck KGaA
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$78B$69B-1.8%-5.9%22.8%24.0%$9.66

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Merck KGaA Valuation Multiples

Merck KGaA trades at 3.2x EV/Revenue multiple, and 11.3x EV/EBITDA.

See NTM and 2027E valuation multiples for Merck KGaA

EV / Revenue (LTM)


Merck KGaA Financial Valuation Multiples

As of July 18, 2026, Merck KGaA has market cap of $69B and EV of $78B.

Merck KGaA has a P/E ratio of 16.9x.

LTMLast FY202320242025202620272028
EV/Revenue3.2x3.2x3.2x3.2x3.2x
EV/EBITDA11.3x11.0x12.0x11.4x11.4x
EV/EBIT16.9x17.1x19.0x16.9x18.6x
EV/Gross Profit5.5x5.5x5.5x5.5x5.5x
P/E16.9x16.3x21.2x21.5x22.9x
EV/FCF27.5x32.9x38.7x28.3x34.5x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Merck KGaA Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Merck KGaA Margins & Growth Rates

Merck KGaA decreased revenue by 1% and EBITDA by 5% in the last fiscal year.

In the most recent fiscal year, Merck KGaA reported gross margin of 58%, EBITDA margin of 29%, and net margin of 17%.

See estimated margins and future growth rates for Merck KGaA

Merck KGaA Margins

Last FY202420252026202720282029
Gross Margin58%59%59%59%
EBITDA Margin29%28%28%28%
EBIT Margin19%19%17%19%
Net Margin17%13%12%16%
FCF Margin10%11%9%13%

Merck KGaA Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth(1%)1%(0%)(0%)
Gross Profit Growth1%1%(1%)1%
EBITDA Growth(5%)5%1%(2%)
EBIT Growth2%12%(9%)11%
Net Profit Growth(6%)(2%)(6%)33%
FCF Growth36%36%(18%)42%

Data powered by FactSet, Inc. and Morningstar, Inc.

Merck KGaA Operational KPIs

Merck KGaA's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.

Merck KGaA's Rule of 40 is 28% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Merck KGaA's Rule of X is 27% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Merck KGaA
LTMLast FY202320242025202620272028
Rule of 4030%28%---
Bessemer Rule of X33%27%---
Revenue per Employee-$0.4M---
Opex per Employee-$0.2M---
S&M Expenses to Revenue21%22%19%19%19%
G&A Expenses to Revenue7%7%7%7%7%
R&D Expenses to Revenue12%11%12%11%11%
Opex to Revenue-41%42%40%41%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Merck KGaA Competitors

Merck KGaA competitors include Regeneron, Chugai Pharma, Takeda Pharmaceuticals, Bayer, argenx, UCB, Jiangsu Hengrui Pharma, Lonza Group, Sun Pharma and Disco.

Most Merck KGaA public comparables operate across Biopharmaceuticals, Life Sciences Tools, Advanced Materials, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Regeneron4.5x4.3x11.2x12.2x
Chugai Pharma8.5x8.3x16.8x15.9x
Takeda Pharmaceuticals2.8x2.8x10.1x10.2x
Bayer1.6x1.6x7.7x7.8x
argenx11.6x9.5x37.5x31.2x
UCB5.7x5.5x16.7x16.1x
Jiangsu Hengrui Pharma9.8x9.2x32.5x31.4x
Lonza Group6.3x6.2x20.0x19.4x

This data is available for Pro users. Sign up to see all Merck KGaA competitors and their valuation data.

Start Free Trial

Acquisitions by Merck KGaA

Merck KGaA has acquired 11 companies to date.

Last acquisition by Merck KGaA was on October 15th 2025. Merck KGaA acquired JSR Life Sciences (chromatography unit) for undisclosed valuation.

See M&A valuation multiples

Latest Acquisitions by Merck KGaA

JSR Life Sciences (chromatography unit)
SpringWorks Therapeutics
UnitySC
Exelead
Description
-
SpringWorks Therapeutics is a Stamford-headquartered clinical-stage biopharmaceutical company developing precision oncology medicines. The lead candidate nirogacestat targets desmoid tumors and received FDA approval in 2023. Pipeline includes gamma secretase inhibitors for solid tumors with Notch pathway activation. Founded in 2017, SpringWorks partners with Roche and Bayer, advancing Phase 3 trials across multiple cancers. The firm trades on NASDAQ under SWTX.
UnitySC is a French firm specializing in metrology and inspection tools for advanced semiconductor packaging. Headquartered in Grenoble, the company supplies defect inspection systems to automotive, high-performance computing, and Internet of Things manufacturers worldwide, backed by global service networks.
Exelead is a contract development and manufacturing organization for lipid nanoparticles and liposomes. Established in 2017 as a subsidiary of Essetifin SpA, it operates from facilities in Indianapolis, Indiana, and Rome, Italy. The company produces formulations for mRNA vaccines, gene therapies, and oncology drugs, supporting clinical trials through GMP-compliant processes. Exelead serves biotech firms developing orphan drugs and rare disease treatments.
HQ CountryUnited StatesUnited StatesFranceUnited States
HQ City
-
Stamford, CT
Grenoble
Indianapolis, IN
Deal Date15 Oct 202528 Apr 20251 Nov 20246 Jan 2022
Valuationundisclosed$3.4B$173M$780M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Merck KGaA acquisitions and their M&A valuation multiples.

Start Free Trial

Investments by Merck KGaA

Merck KGaA has invested in 4 companies to date.

Latest investment by Merck KGaA was on November 20th 2025. Merck KGaA invested in Cassidy Bio in their $8M Seed round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by Merck KGaA

Cassidy Bio
INBRAIN Neuroelectronics
Idrx
Nucleai
Description
Cassidy Bio is a San Francisco-based biotechnology company building AI foundation models for genomic analysis to identify novel drug targets. Its platform processes multi-omics data for precision medicine applications in oncology and rare diseases.
INBRAIN Neuroelectronics is a Barcelona-based neurotechnology firm developing the first graphene-based brain-computer interface platform for precision neurology. Its therapeutics target Parkinson's disease, epilepsy, and stroke recovery via real-time neural decoding and micrometric stimulation for adaptive treatments. The AI-powered system enables continuous monitoring and automated therapy adjustments. Partnerships include Merck KGaA, with subsidiary INNERVIA Bioelectronics expanding to peripheral nerves and systemic applications.
Idrx is a Shanghai-based clinical-stage biopharmaceutical company focused on precision oncology therapies for gastrointestinal stromal tumors. It engineers drug combinations targeting tumor escape mechanisms to extend treatment responses. The pipeline includes KIT-mutant inhibitors in Phase 1/2 trials, addressing unmet needs in resistant patient populations worldwide.
-
HQ CountryIsraelSpainUnited StatesUnited States
HQ City
Tel Aviv
Barcelona
-
-
Deal Date20 Nov 202529 Oct 20247 Aug 20243 Apr 2024
RoundSeedSeries BSeries BSeries A
Raised$8M$50M$120M$14M
InvestorsMerck KGaA; 10D; AstraZeneca; lool ventures; Ahren Innovation CapitalMerck KGaA; European Innovation Council; Vsquared Ventures; Avançsa; Next Tech Fund; Aliath Bioventures; Asabys Partners; Centre for the Development of Industrial Technology (CDTI); imec.xpandMerck KGaA; Nextech Invest; Forge Life Science Partners; Casdin Capital; Blackstone; Andreessen Horowitz; RA Capital Management; Commodore Capital; Nick LydonMerck KGaA; M Ventures; Grove Ventures
Valuationundisclosedundisclosed$415Mundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Merck KGaA investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Merck KGaA

Where is Merck KGaA headquartered?Merck KGaA is headquartered in Germany.
How many employees does Merck KGaA have?As of today, Merck KGaA has over 62K employees.
Is Merck KGaA publicly listed?Yes, Merck KGaA is a public company listed on Frankfurt Stock Exchange.
What is the stock symbol of Merck KGaA?Merck KGaA trades under MRK ticker.
When did Merck KGaA go public?Merck KGaA went public in 1995.
Who are competitors of Merck KGaA?Merck KGaA main competitors include Regeneron, Chugai Pharma, Takeda Pharmaceuticals, Bayer, argenx, UCB, Jiangsu Hengrui Pharma, Lonza Group, Sun Pharma, Disco.
What is the current market cap of Merck KGaA?Merck KGaA's current market cap is $69B.
What is the current revenue of Merck KGaA?Merck KGaA's last 12 months revenue is $24B.
What is the current revenue growth of Merck KGaA?Merck KGaA revenue growth (NTM/LTM) is 2%.
What is the current EV/Revenue multiple of Merck KGaA?Current revenue multiple of Merck KGaA is 3.2x.
What is the current EBITDA of Merck KGaA?Merck KGaA's last 12 months EBITDA is $6.9B.
What is Merck KGaA's EBITDA margin?Merck KGaA's last 12 months EBITDA margin is 28%.
What is the current EV/EBITDA multiple of Merck KGaA?Current EBITDA multiple of Merck KGaA is 11.3x.
What is the current FCF of Merck KGaA?Merck KGaA's last 12 months FCF is $2.8B.
What is Merck KGaA's FCF margin?Merck KGaA's last 12 months FCF margin is 12%.
What is the current EV/FCF multiple of Merck KGaA?Current FCF multiple of Merck KGaA is 27.5x.
How many companies Merck KGaA has acquired to date?As of July 2026, Merck KGaA has acquired 11 companies.
In how many companies Merck KGaA has invested to date?As of July 2026, Merck KGaA has invested in 4 companies.
What was the last Merck KGaA investment?On 20th November 2025 Merck KGaA invested in Cassidy Bio, participating in a $8M Seed round, alongside 10D, AstraZeneca, lool ventures, and Ahren Innovation Capital.
In what companies Merck KGaA invested in?Merck KGaA invested in Idrx, INBRAIN Neuroelectronics, Nucleai, and Cassidy Bio.

See public comps similar to Merck KGaA

Lists including Merck KGaA

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial